Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributable to the company, compared with net loss of $217 million, or $0.19 per share, last year.
On an adjusted basis, earnings increased to $1.130 billion, or $0.96 per share, from $816 million, or $0.71 per share, in the previous year.
Analysts, on average, estimated earnings of $0.64 per share for the quarter.
Revenue went up to $4.711 billion from $4.229 billion in the prior year, mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug and from higher revenues from our key innovative products.
Looking ahead, the company sees full year 2026 revenue outlook of $16.4 - $16.8 billion and adjusted earnings of $2.57 - $2.77 per share.
On average, analysts anticipate earnings of $2.77 per share and revenue of $16.99 billion for the full year 2026.
In the pre-market hours, TEVA is trading at $32.55, up 0.08 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.